Table 4 Adjusted screening performance measurements with 95% confidence intervals using GEE to account for correlations between mammograms of the same woman and to correct for the confounders percent dense volume and breast volume
| Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | |
|---|---|---|---|---|---|
| Recall/1000 |
26.1 (24.0–28.5) |
20.8 (19.1–22.6) |
22.0 (20.3–23.9) |
21.0 (19.3–22.8) |
22.2 (20.3–24.3) |
| False positives/1000 |
20.0 (18.1–22.1) |
14.8 (13.4–16.4) |
15.1 (13.7–16.6) |
15.2 (13.8–16.8) |
16.2 (14.6–18.0) |
| Screen-detected cancers/1000 |
6.1 (5.2–7.2) |
5.9 (5.0–6.9) |
6.9 (6.0–8.0) |
5.7 (4.9–6.7) |
5.9 (4.9–7.0) |
| Interval cancers/1000 |
1.3 (0.9–1.8) |
1.6 (1.2–2.2) |
1.6 (1.2–2.1) |
2.2 (1.7–2.8) |
2.3 (1.7–3.0) |
| Program sensitivity (%)* |
82.0 (75.6–87.0) |
77.1 (70.9–82.4) |
79.8 (74.2–84.4) |
71.1 (64.5–79.8) |
70.8 (63.6–77.1) |
| 12 month sensitivity (%)** |
90.1 (84.4–93.9) |
92.0 (87.2–95.1) |
93.9a
(89.7–96.5) |
87.2 (81.3–91.4) |
84.3a
(77.3–89.4) |
| Specificity (%) |
98.0a,b,c
(97.8–98.2) |
98.5a
(98.3–98.7) |
98.5b
(98.3–98.6) |
98.5c
(98.3–98.6) |
98.4 (98.2–98.5) |
| Positive predictive value (%) |
23.5 (20.2–27.3) |
28.7 (25.0–32.7) |
31.5 (27.9–35.3) |
27.3 (23.7–31.1) |
26.7 (22.9–30.8) |